Literature DB >> 29678279

The Psychiatric Consequences of Cannabinoids.

Joao P De Aquino1, Mohamed Sherif1, Rajiv Radhakrishnan1, John D Cahill2, Mohini Ranganathan1, Deepak C D'Souza3.   

Abstract

With rising rates of cannabis use in the general population and an increasing number of US states legalizing both recreational and medical cannabis use, it is important to be informed about the adverse consequences of cannabinoids. This Commentary provides an overview of the psychiatric effects of plant-based and synthetic cannabinoids, differentiating acute effects from effects associated with persistent use. Cannabinoids produce multiphasic and dose-dependent effects on anxiety, mood, and perception, in addition to impairing cognition and psychomotor function. Generally, in healthy individuals, the acute negative psychiatric effects of cannabinoids are rated as milder in severity compared with those in individuals with pre-existing psychiatric disorders. With chronic exposure to cannabinoids, the probability of developing tolerance and dependence can increase. A problematic pattern of cannabis use can lead to clinically significant impairment and distress. Cessation of cannabis use in individuals who are tolerant and dependent can lead to a withdrawal syndrome. Studies report long-term cannabis exposure has been linked to psychiatric disorders, such as anxiety, psychotic and mood disorders. Limitations to the existing evidence notwithstanding, the plausibility of a causal relationship between cannabinoid exposure and persistent negative psychiatric outcomes, and the potential for long-term brain changes by regular exposure, especially for adolescents, are sufficient to warrant discussions with clinicians and the public. Implications for clinicians who certify, prescribe, or care for patients receiving cannabinoids are discussed, and a case is made for further research to better understand the impact of legalization on public mental health.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  cannabinoid; cannabis; medical marijuana; psychiatric; side effects

Mesh:

Substances:

Year:  2018        PMID: 29678279     DOI: 10.1016/j.clinthera.2018.03.013

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  13 in total

1.  Disagreement and Uncertainty Among Experts About how to Respond to Marijuana Use in Patients on Long-term Opioids for Chronic Pain: Results of a Delphi Study.

Authors:  Joanna L Starrels; Sarah R Young; Soraya S Azari; William C Becker; E Jennifer Edelman; Jane M Liebschutz; Jamie Pomeranz; Payel Roy; Shalini Saini; Jessica S Merlin
Journal:  Pain Med       Date:  2020-02-01       Impact factor: 3.750

2.  Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.

Authors:  Dawn E Sugarman; Joao P De Aquino; James Poling; Mehmet Sofuoglu
Journal:  Pharmacol Biochem Behav       Date:  2019-05-10       Impact factor: 3.533

3.  The perils of recreational marijuana use: relationships with mental health among emergency department patients.

Authors:  Catherine A Marco; John Paul Detherage; Ashley LaFountain; Megan Hanna; Justin Anderson; Rachel Rhee; Jacqueline Ziegman; Dennis Mann
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-03-08

4.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

5.  Cannabinoids and Pain: Weeding Out Undesired Effects With a Novel Approach to Analgesia.

Authors:  Joao P De Aquino; David A Ross
Journal:  Biol Psychiatry       Date:  2018-11-15       Impact factor: 13.382

Review 6.  Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination.

Authors:  Joana Gonçalves; Tiago Rosado; Sofia Soares; Ana Y Simão; Débora Caramelo; Ângelo Luís; Nicolás Fernández; Mário Barroso; Eugenia Gallardo; Ana Paula Duarte
Journal:  Medicines (Basel)       Date:  2019-02-23

Review 7.  Cannabinoids in Glaucoma Patients: The Never-Ending Story.

Authors:  Andrea Passani; Chiara Posarelli; Angela Tindara Sframeli; Laura Perciballi; Marco Pellegrini; Gianluca Guidi; Michele Figus
Journal:  J Clin Med       Date:  2020-12-08       Impact factor: 4.241

Review 8.  Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.

Authors:  Zeinab Breijyeh; Buthaina Jubeh; Sabino A Bufo; Rafik Karaman; Laura Scrano
Journal:  Toxins (Basel)       Date:  2021-02-05       Impact factor: 4.546

9.  Patterns of Cannabis Use Among Individuals with Obsessive-Compulsive Disorder: Results from an Internet Survey.

Authors:  Reilly R Kayser; Meredith S Senter; Rebecca Tobet; Marissa Raskin; Sapana Patel; H Blair Simpson
Journal:  J Obsessive Compuls Relat Disord       Date:  2021-07-13       Impact factor: 2.236

10.  Δ-Tetrahydrocannabinol Increases Dopamine D1-D2 Receptor Heteromer and Elicits Phenotypic Reprogramming in Adult Primate Striatal Neurons.

Authors:  Ahmed Hasbi; Bertha K Madras; Jack Bergman; Stephen Kohut; Zhicheng Lin; Sarah L Withey; Susan R George
Journal:  iScience       Date:  2019-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.